the diagnosis, aim of therapy, the GTV(s), the CTV(s), prescribed dose, and fractionation. It must be easy to include information necessary for treatment planning as well as relevant treatment parameters resulting from planning. The form must provide the technician with all details concerning the actual patient setup, and it must also be possible to use it as a log-book to enter notes on every given fraction. For control purposes, it must be possible to prescribe and record all dose measurements and other types of patient supervision and control of treatment together with the corresponding measures taken. The form must provide the supervising physician with adequate information to correctly evaluate the reactions of the patient during the entire course of treatment. After conclusion of treatment, all values of doses and time must be summarized to give the final dose/time values for the different volumes (PTV s and organs at risk). The code given here is a suggestion of how an internationally accepted classification can be used to describe the Gross Tumor Volume and Clinical Target Volume. It is an adaptation from the International Classification of Diseases for Oncology, ICD-O, 2nd Edition (WHO, 1990) , which, in turn, is based on the proposed 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (lCD-lO).
Since the ICD-O is not specific enough to describe anatomical structures in sufficient detail, a letter has been added to accomodate the necessary subsites for skin, soft tissue, bone, and lymph nodes. Laterality is also added by using the code for laterality from WHO Handbook for Standardized Cancer Registries (WHO, 1976b) as follows:
The full code thus has this format: The data should be unambiguous, and should also follow accepted concepts and definitions, in order to allow for pooling of information from a group of patients for evaluation. The record form must contain sufficient information for legal purposes, should such need arise. In order to meet these requirements, certain mandatory data will have to be recorded. Furthermore, for the interpretation of treatment results, it may be useful also to record other data, which, from the point of view of the individual patient, may be considered to be optional.
A list of the different parameters that may be considered useful to be recorded is given in Table 1 .1. It conforms with the recommendations given in Report 42 [ICRU, 1987] .
It may, for retrieval purposes, be useful to digitize the anatomical locations ofthe GTV and CTV as well as the location of sections for dose planning. Codes for these purposes are presented in Tables 1.2. and 1.3.
Description of Treatment Technique, Including Methods for Planning, Dose Calculation and Control, for the Purpose of Reporting
For reporting, it is recommended that the planning, technique, calculation, and control methods are described on the basis of the guidelines given below.
Treatment Planning
(i) Patient positioning (e.g., prone/supine, head/ feet towards stand, sitting, etc.). (ii) Immobilization devices (e.g., plaster of Paris cast, vacuum cast, bite blocks, etc.). (iii) Localization and simulation performed at simulator or at treatment machine. (iv) Treatment planning based on computed tomography or other relevant information. (v) Optimization of dose distribution at the computer or at the simulator.
Technique
(i) Number and arrangement, location, and direction of the beams in relation to the patient. (ii) Stationary beams with SAD or SSD technique and distance, or moving beam technique and arc. (iii) Field sizes: geometrical field size usually corresponds to the 50 per cent isodose curve. For fixed SSD, the field size is usually given at the skin, for fixed SAD the field size is usually given at the isocenter. When field borders are parallel to the planning section, the field size in the section should be given first. 
c. Abdominal Hodgkin's disease, stage II (the figure illustrating GTV is taken and modified from TNM Atlas [UICC, 1982] ).
Medulloblastoma of 4th ventricle
Anatomical structure ICD-O(9) ICD-O(10) Laterality T-SNOMED 
Quality Control
(i) Check and confirm systems. (ii) Verification imaging (when during treatment, frequency, and acceptability). (iii) In-vivo dosimetry (type of measurements, frequency, and acceptability).
Special Comments
The reporting of absorbed dose for external beam therapy should be accompanied by information on the time dose pattern including, at least, the number of fractions and the overall time (in days). The first and the last day of treatment are then included. Unless otherwise stated, it is understood that the fractionation is regular (5 times per week) with equal fractions, all fields being irradiated at each fraction. The position and length of any gap or interruption must be given as well as any change in dose per fraction. All transverse sections of the patient should be as viewed from the foot end of the patient irrespective of the patient position. The right and the left side of the section should be indicated (e.g., Dxt/Sin, or Right/Left). For other sections, the orientation should also be clearly indicated in the figure.
For comparison purposes, 60CO gamma rays should be taken as the reference radiation. The same RBE applies for photon radiations with a nominal energy of at least 2 MV, and for electron radiation in the range 1-50 MeV. For orthovoltage x-ray therapy, the RBE is larger than unity value, and a conversion factor of 1.18 may be considered adequate for the normal radiotherapy procedures. If RBE-corrected values are reported, this should be stated. When isodose curves are shown (relative or absolute values), care should be taken so that the correct !;lumber is unambiguously related to the correct isodose line. It is an advantage if, e.g., the "hotter" side of an isodose can be indicated, since this will, in some instances, indicate if a small volume/ area is a hotter area or cooler area than the surroundings. When isodose plots are shown with relative dose values, it is an advantage if the isodose through the ICRU Reference Point is given the relative value 100%. A report on radiation therapy must always give the absorbed dose(s) in Gy or cGy. Furthermore, biologically weighted doses, calculated according to specified biological models may be of interest.
Recording of target absorbed dose rate may be useful, and is recommended for values below 0.1 Gy per minute for any part of the Planning Target Volume. It should always be clearly stated if correction for tissue inhomogeneity has been carried out or not when calculating the absorbed doses.
The method used for calculation should also be reported. If corrected values are reported, then, for intercomparison purposes, the uncorrected values should also be given (see section 3.3.3).
